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In this issue of Blood, Akagi and colleagues demonstrate the importance of the CCAAT enhancer binding protein ␤ (C/EBP␤) for granulocyte function and survival. Their novel findings further elucidate the variety of C/EBP protein functions in general and the special role of C/EBP␤ in particular.
C
/EBP proteins are a family of leucine zipper domain-containing transcription factors that form homodimers and heterodimers to regulate expression of their target genes. C/EBP proteins play important roles in differentiation events in diverse tissues, and several of them inhibit proliferation. In the hematopoietic system, C/EBP␣ is essential for granulocytic lineage commitment. Further downstream, C/EBP⑀ directs the differentiation of progenitors into mature neutrophils. These functions are well established by the lack of respective cell populations in genetically modified mice. C/EBP␤ is also highly expressed in mature granulocytes, but the lack of C/EBP␤ does not alter steady-state bone marrow morphology or peripheral-blood cell counts. 1 Thus, the function of C/EBP␤ in myeloid development has remained obscure for some time.
Interest in C/EBP␤ was fueled by its diverse and seemingly contradictory functions. 2 In many instances, C/EBP␤ appeared to be redundant with C/EBP␣; a C/EBP␤ knock-in into the C/EBP␣ locus rescues most of the C/EBP␣ deficiency phenotype. However, other reports have suggested that C/EBP␤ is required for the oncogenic functions of Ras. The differences between C/EBP␣ and C/EBP␤ are likely to be associated with the cell-specific expression pattern, the close interaction between C/EBP␤ and cytokine signaling, and the interaction partners of the 2 proteins. In contrast to C/EBP␣, C/EBP␤ does not interact with E2F, and this may explain why C/EBP␤ does not cause cell-cycle arrest. In addition, expression of the 2 main isoforms of C/EBP␣ and C/EBP␤, which are controlled translationally, may be regulated differentially depending on cell stimulus.
Analysis of C/EBP␤-deficient mice revealed a high susceptibility to bacterial infections. C/EBP␤-deficient macrophages showed impaired killing of bacteria and tumor cells. Recently, Hiari et al discovered that C/EBP␤ plays an important role in emergency granulopoiesis. 1 Upon exposure to cytokines or infectious agents in vivo, C/EBP␤ expression is induced, which leads to generation of responsive granulocytes even in the absence of C/EBP␣. These findings established that C/EBP␤ plays an important role in granulopoiesis under critical conditions such as severe infection. The current study by Akagi et al significantly extends these findings: C/EBP␤ deficiency decreased cytokine production and colony growth of myeloid, but not erythroid or megakaryocytic progenitors. Importantly, C/EBP␤ deficiency also increased apoptotic cell death of granulocytes. This specific feature of C/EBP␤ in neutophils also occurs in other cell types. The antiapoptotic functions of C/EBP␤ are in direct contrast to other C/EBPs, such as C/EBP␣, that induce apoptosis.
It is intriguing to speculate that granulocytes might be regulated by C/EBP␣ and C/EBP⑀ to maintain a steady state. This would also include regular apoptotic death and a well-maintained balance between proliferation and differentiation. Under critical circumstances, such as severe infection, C/EBP␤ not only enhances granulocyte production but also increases granulocyte numbers by inhibiting apoptosis. In addition, upon cytokine stimulation, C/EBP␤ boosts granulocyte function and might help to overcome infection. The findings by Akagi et al further integrate growth-factor and cytokine signaling with the transcription-factor networks that govern these processes (see figure) . G-CSF is an established treatment for several diseases that cause neutropenia; further studies may show whether C/EBP␤ function is crucial for G-CSF treatment successes, such as increased numbers of granulocytes caused by increased production and extended lifespan. Moreover, further studies are needed to elucidate the mechanisms by which C/EBP␤ Role of C/EBP␤ in granulopoiesis and granulocyte function. C/EBP␣ is required for granulopoiesis in steady-state conditions. As a response to external stimuli, such as sever infection or growth factor exposure, C/EBP␤ enhances granulocyte production, inhibits apoptosis, and induces production of IL-6, IL-10, and IL-12 p35. 
As the authors note, the phenotypic features of C/EBP␤-deficient granulopoiesis resemble those of a myelodysplastic syndrome. Because C/EBP␣ mutations and/or dysfunction are known to be involved in the pathogenesis of acute myeloid leukemia (AML), it is possible that inactivation of other C/EBP proteins such as C/EBP␤ play a role in myeloid disorders (MDSs) as well. For example, C/EBP␦ is frequently inactivated by promoter methylation in AML, 3 and it is possible that C/EBP␤ function might be altered in myeloid malignancies and MDSs. Also, the findings by Akagi et al clearly show that a normal white blood cell count in a genetic mouse model can, under steady-state conditions, conceal an important function of the gene in hematopoiesis.
The critical importance of granulopoiesis and granulocyte function in hematology and clinical medicine is obvious, and we have made a lot of progress in deciphering its mechanisms. Nonetheless, tools to more effectively and specifically manipulate granulocyte functions and productions are necessary. The findings presented by Akagi and colleagues might help to design new strategies for overcoming neutropenia and granulocyte dysfunction.
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More ADO about IDO: GVHD   -------------------------------------------------------------------------------------------------------------- 
I
DO is a key enzyme in tryptophan metabolism that catalyzes the initial ratelimiting step of tryptophan degradation along the kynurenine pathway. 1 Tryptophan starvation by IDO consumption inhibits T-cell activation, while products of tryptophan catabolism, such as kynurenine derivatives and O 2 free radicals, regulate T-cell proliferation and survival. 1,2 Based on these activities, IDO has immunosuppressive function. Accordingly, cell populations, including regulatory dendritic cells, 3 express the functionally active form of IDO, resulting in the suppression of T-cell responses to autoantigens and alloantigens. 1, 3 Recently, human malignancies including acute myeloid leukemia have been demonstrated to express an active IDO protein, which mediates T-cell tolerance to tumors. 4, 5 Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality after allogeneic stem-cell transplantation. In recent years, our knowledge of the pathophysiology of GVHD has increased, but the immunological mechanisms by which GVHD is regulated at both local and systemic levels are still incompletely understood. Jasperson and colleagues have elegantly used an IDO Ϫ/Ϫ knock-out mouse model to investigate the role of IDO in the context of GVHD. Donor T cells were strictly required to up-regulate IDO expression in gut epithelial cells, and the absence of IDO resulted in increased colon GVHD, which, in turn, shortened survival of IDO Ϫ/Ϫ mice that had received transplants as compared with wt mice. Interestingly, in IDO Ϫ/Ϫ mice the major effect is described at the site of GVHD, mainly in the gut, with increased infiltration of proliferating CD4 ϩ and CD8 ϩ T cells, whereas little, if any, systemic effect was found (ie, activation of T cells in lymphoid organs and/or induction of T regulatory cells [Tregs] ).
This study reports novel findings that may have significant clinical implications. In particular, the critical role of IDO expression in orchestrating T-cell function during GVHD at the site of inflammation represents a major advance in our knowledge of the environmental effects influencing GVHD tissue injury. Moreover, these results offer a rationale for a novel approach to GVHD management. The modulation of IDO in GVHD target organs may represent an interesting strategy for limiting GVHD by acting at sites where host and donor cells interact, whereas other interventions, such as Treg-infusion therapy, may be used to induce systemic T-cell tolerance within lymphoid organs. However, an effective clinical approach to activate or enhance IDO expression once GVHD has been initiated remains to be elucidated. The preemptive induction of IDO in GVHD target organs before the occurrence of GVHD may have a more relevant clinical impact. However, the lack of IDO expression in other GVHD target tissues, such as liver and skin, indicates that mechanisms other than modulation of tryptophan catabolism may be operative in limiting GVHD in some locations. Future studies addressing these points are warranted.
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